The recent surge of C. difficile infections over the past 10 years has brought a concern over dealing with an infection borne out of antibiotic overuse. New approaches to fighting infection are needed and may be found in the virulence factors of the microbe itself. The A and B cytotoxin production, the main virulence factors of C. difficile, may be silenced by modifying the use of the active immune system, CRISPR, for self targeting and delivery into the bacterial genome in vivo by use of modified temperate phage. This treatment can be used individually or to enhance other antibiotic sensitive treatments.